| Literature DB >> 29731394 |
Matthew D Hellmann1, Margaret K Callahan2, Mark M Awad3, Emiliano Calvo4, Paolo A Ascierto5, Akin Atmaca6, Naiyer A Rizvi7, Fred R Hirsch8, Giovanni Selvaggi9, Joseph D Szustakowski10, Ariella Sasson10, Ryan Golhar10, Patrik Vitazka10, Han Chang10, William J Geese10, Scott J Antonia11.
Abstract
Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutational burden on efficacy of nivolumab monotherapy or combined with ipilimumab in patients with SCLC from the nonrandomized or randomized cohorts of CheckMate 032. Patients received nivolumab (3 mg/kg every 2 weeks) or nivolumab plus ipilimumab (1 mg/kg plus 3 mg/kg every 3 weeks for four cycles, followed by nivolumab 3 mg/kg every 2 weeks). Efficacy of nivolumab ± ipilimumab was enhanced in patients with high tumor mutational burden. Nivolumab plus ipilimumab appeared to provide a greater clinical benefit than nivolumab monotherapy in the high tumor mutational burden tertile.Entities:
Keywords: CTLA-4; PD-1; biomarkers; clinical trial; immunotherapy; ipilimumab; nivolumab; small cell lung cancer; tumor mutation burden
Mesh：
Substances：
Year: 2018 PMID： 29731394 PMCID： PMC6750707 DOI： 10.1016/j.ccell.2018.04.001
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743